FDA advisory panel backs approval of J&J's hepatitis C drug

Thu Oct 24, 2013 4:43pm EDT

Related Topics

(Reuters) - An advisory committee of the U.S. Food and Drug Administration voted unanimously to approve Johnson & Johnson's hepatitis C drug, J&J said on Thursday.

The panel voted 19-0 in favor of the drug, simeprevir, which was tested in combination with standard hepatitis C drugs, peginterferon-alpha and ribavirin.

The drug is being developed by J&J unit Janssen Research & Development LLC. It is being tested in adults who failed previous interferon-based therapy or had not received medication at all.

The FDA usually follows the recommendation of the advisory panel, although it is not obligated to do so.

Hepatitis C, an infection of the liver transmitted through the blood, kills more than 15,000 Americans each year, mostly from hepatitis C-related illnesses such as cirrhosis and liver cancer.

J&J shares closed at $92.35 on the New York Stock Exchange on Thursday.

(Reporting By Adithya Venkatesan in Bangalore; Editing by Maju Samuel)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

California state worker Albert Jagow (L) goes over his retirement options with Calpers Retirement Program Specialist JeanAnn Kirkpatrick at the Calpers regional office in Sacramento, California October 21, 2009. Calpers, the largest U.S. public pension fund, manages retirement benefits for more than 1.6 million people, with assets comparable in value to the entire GDP of Israel. The Calpers investment portfolio had a historic drop in value, going from a peak of $250 billion in the fall of 2007 to $167 billion in March 2009, a loss of about a third during that period. It is now around $200 billion. REUTERS/Max Whittaker   (UNITED STATES) - RTXPWOZ

How to get out of debt

Financial adviser Eric Brotman offers strategies for cutting debt from student loans and elder care -- and how to avoid money woes in the first place.  Video